1 |
Ahmet D, Kucukzeybek Y, Erten C, et al (2013). prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5
DOI
ScienceOn
|
2 |
Athar U, Gentile TC (2008). Treatment options for metastatic renal cell carcinoma: a review. Can J Urol, 15, 3954-66
|
3 |
Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34.
DOI
|
4 |
Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 357, 203.
|
5 |
Escudier B, Pluzanska A, Koralewski P, et al (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103-11.
DOI
|
6 |
Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol, 12, 1143-50.
DOI
|
7 |
Gore ME, Szczylik C, Porta C, et al (2009). Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded access trial. Lancet Oncol, 10, 757-63
DOI
|
8 |
He Z, Guo G, Zhang C, et al (2014). Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers. Chinese Med J, 127, 1450-53
|
9 |
Herrmann E, Bierer S, Wulfing C (2010). Update on systemic therapies of metastatic renal cell carcinoma. World J Urol, 28, 303-9 .
DOI
|
10 |
Hong MH, Kim HS, Kim C, et al (2009). Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat, 41, 67-72.
DOI
|
11 |
Inamoto T, Azuma H, Nonomura N, et al (2014). Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group. Asian Pac J Cancer Prev, 15, 1811-5
DOI
|
12 |
Kim HS, Hong MH, Kim K, et al (2011). Sunitinib for asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles. Oncology, 80, 395-405
DOI
|
13 |
Krishna VM, Noronha V, Prabhash K, et al (2013) Sunitinib in metastatic renal cell carcimoma: A single-center experience. Indian J Cancer July, 50, 268-73
DOI
|
14 |
Law TM, Motzer RJ, Mazumdar M, et al (1995). Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76, 824-32.
DOI
|
15 |
Lee S-H, Bang Y-J, Mainwaring P, et al (2014). Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clinical Oncol, 10, 237-45
DOI
|
16 |
Motzer RJ, Rini BI, Bukowski RM, et al (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24
DOI
|
17 |
Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor ,and platelet derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24
DOI
|
18 |
Na X, Wu G, Ryan CK, et al (2003). Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol, 170, 588-92.
DOI
|
19 |
Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24.
DOI
|
20 |
Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 227, 3584.
|
21 |
Negrier S, Escudier B, Lasset C, et al (1998). Recombinant human interleukin-2, recombinant human interferonalfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med, 338, 1272-8
DOI
|
22 |
Porta C, Procopio G, Carteni G, et al (2011). Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicenter retrospective analysis of 189 patient cases. BJU Int, 108, 250-7.
DOI
ScienceOn
|
23 |
Rini BI, Small EJ (2005). Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol, 23, 1028-43.
|
24 |
Rini BI, Campbell SC, Escudier B (2009). Renal cell carcinoma. Lancet, 373, 1119
DOI
ScienceOn
|
25 |
Turner KJ, Moore JW, Jones A, et al (2002). Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von hippel-lindau gene mutation. Cancer Res, 62, 2957.
|
26 |
Uemura H, Shinohara N, Yuasa T, et al (2010). A Phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol, 40, 194-202.
DOI
|
27 |
Yoo C, Kim J-E, Lee J-L, et al (2010). The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol, 40, 980-5
DOI
|
28 |
van Erp NP, Eechoute K, van der Veldt AA, et al (2009). Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol, 27, 4406-12.
DOI
ScienceOn
|